Neurocrine Signs a License Agreement with Xenon to Develop Therapies for Epilepsy

 Neurocrine Signs a License Agreement with Xenon to Develop Therapies for Epilepsy

Neurocrine Signs a License Agreement with Xenon to Develop Therapies for Epilepsy

Shots:

  • Neurocrine to receive exclusive license to Xenon’s XEN901 including two preclinical candidates including selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors involving activities to discover, develop and identify additional novel Nav1.6 and Nav1.2/1.6 inhibitors
  •  Neurocrine Biosciences will fund all clinical developments costs associated with products including funding of 3 years research collaboration with a minimum of 10 FTEs while Xenon will be responsible for certain pre-clinical and a portion of certain near-term manufacturing costs
  • Xenon to get $50M upfront including $30M in cash and $20M equity investment at Xenon/share price of $14.19, milestones $25M on IND acceptance of XEN901 including 55% equity investment at 15% premium, additional milestones of $1.7B related to XEN901, Nav1.6 or Nav1.2/1.6 candidates, royalties on sales. Xenon will also co-fund 50% of US cost for XEN901 and will receive 20% increased royalties for other candidates in the US
  • XEN901 is a highly selective Nav1.6 sodium channel inhibitor developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and has completed its P-I trial with expected filing an IND application in mid- 2020

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post